Clinical Trial: A Multicenter, Single-Arm, Exploratory Study of Ipaloritol Vorlimab Combined with Disitamab Vedotin and S-1 in the Neoadjuvant Treatment of Locally Advanced HER2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma (China)

China, Aug. 25 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'A Multicenter, Single-Arm, Exploratory Study of Ipaloritol Vorlimab Combined with Disitamab Vedotin and S-1 in the Neoadjuvant Treatment of Locally Advanced HER2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600130765

Registration Time: 2026/08/24

Type: Interventional study

Primary Sponsor: Fuzhou University Affiliated Provincial Hospital

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=339107

Published by HT Digital Content Services with permission from Health Daily Digest....